Showing 5761-5770 of 5949 results for "".
- ZO Skin Health Opens in Pasadenahttps://practicaldermatology.com/news/20121203-zo_skin_health_opens_in_pasadena/2459666/ZO® Skin Health, described as a cutting-edge center that offers the latest in skin transformation and anti-aging technology and treats a wide range of skin conditions including acne, scars, large pores and skin imperfections, opened November
- CryoShape Uses Cold to Reduce Scarshttps://practicaldermatology.com/news/20121203-cryoshape_uses_cold_to_reduce_scars/2459667/CryoShape is a patented handheld device for treating keloid and hypertrophic scars. Physicians can destroy deep tissue using an extremely cold probe that is injected directly into the scar. Treating scars with cold freezes them from the inside,
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- New Data Show Stelara Effective for Psoriatic Arthritishttps://practicaldermatology.com/news/20121203-new_data_finds_stelara_effective_for_psoriatic_arthritis/2459669/Findings from the PSUMMIT II Phase 3 investigational study showed patients with active psoriatic arthritis receiving Stelara (ustekinumab, Jannsen) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patie
- Jonah Shacknai Honored at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20121203-jonah_shacknai_honored_at_cosmetic_surgery_forum/2459670/Innovators in the field of cosmetic dermatology were honored this past weekend at Cosmetic Surgery Forum, a discussion-based CME symposium held in Las Vegas and now in its fourth year. Jonah Shacknai, Founder of Medicis, was the recipient of the Lifetime Achievement in Dermatology Award. On receivin
- Jurlique Purely Bright Releases Clinical Resultshttps://practicaldermatology.com/news/20121128-jurlique_purely_bright_releases_clinical_results/2459672/Jurlique Purely Bright, a brightening system launched earlier this year, released clinical results on its product line. After 30 days, the system was clinically proven to help reduce dark spots. After 12 weeks, skin surface smoothness doubled at
- Grants Awarded from National Rosacea Societyhttps://practicaldermatology.com/news/20121127-grants_awarded_from_national_rosacea_society/2459673/The National Rosacea Society (NRS) awarded funding to five new studies as part of its research grants program to increase knowledge and understanding of rosacea. Dr. Anna Di Nardo, associate professor of medicine at the University of California-San Diego, received $25,000 to study the role of mast c
- Valeant Receives FTC Clearance For Medicis Acquisitionhttps://practicaldermatology.com/news/20121121-valeant_receives_ftc_clearance_for_medicis_acquisition/2459676/The US Federal Trade Commission (FTC) granted early termination of the waiting period surrounding the proposed acquisition of Medicis Pharmaceutical Corporation by Valeant Pharmaceuticals International, Inc., effective November 15, 2012. The propo
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has